Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders
Inozyme Pharma Inc (NASDAQ:INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6…
51 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors.
Why Inozyme Pharma Shares Are Jumping Today
Inozyme Pharma Inc (NASDAQ:INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase…
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
HC Wainwright & Co. Initiates Coverage On Inozyme Pharma with Buy Rating, Announces Price Target of $33
HC Wainwright & Co. analyst Edward White initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Buy rating and announces Price Target of $33.
Inozyme Pharma Q3 EPS $(0.60) Up From $(1.55) YoY
Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.60) per share. This is a 61.29 percent increase over losses of $(1.55) per share from the same period last year.
